Anti-SERT-SAP utilizes a monoclonal antibody to the fourth extracellular domain of the serotonin re-uptake transporter (SERT). The sequence of the peptide antigen is identical in rat, mouse, human, and other mammalian species. SERT is the major determinant of serotonin inactivation following release at synapses, is the site of action for many tricyclic antidepressants and the SSRIs (serotonin-selective reuptake inhibitors), and is also targeted by a number of psychostimulants including cocaine, methylphenidate, and MDMA ‘ecstasy.’ SERT is produced from a single gene and is expressed in both the CNS and GI system.
Decreased serotonergic neurotransmission has been proposed to play a key role in the etiology of depression. Recent findings suggest that SERT might be linked to both neurotic and sexual behavior as well as to obsessive-compulsive disorder (OCD). Anti-SERT-SAP specifically eliminates cells expressing SERT making it an excellent tool for studying the sertonergic system which is known to modulate mood, emotion, sleep and appetite and thus is implicated in the control of numerous behavioral and physiological functions.
Anti-SERT-SAP is a chemical conjugate of a monoclonal antibody to the fourth extracellular domain of serotonin re-uptake transporter (SERT) and the ribosome-inactivating protein, saporin. It specifically eliminates SERT-expressing cells in vitro and in vivo.